21/05/2026 Junshi Biosciences secures NMPA approval for toripalimab + disitamab vedotin in HER2+ urothelial carcinoma Kelun-Biotech's Phase III sac-TMT Trial meets Primary PFS Endpoint in First-Line Advanced TNBC Junshi Biosciences secures NMPA approval for toripalimab + disitamab vedotin in HER2+ urothelial carcinoma (Ref) China’s NMPA approved toripalimab + disitamab vedotin for first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma (UC)

16/05/2026 ImPact Biotech’s padeliporfin VTP delivers 70% complete response with durable safety in Phase 3 LG‑UTUC, setting up 2027 regulatory submission and expansion into solid tumors ImPact Biotech’s padeliporfin VTP delivers 70% complete response with durable safety in Phase 3 LG‑UTUC, setting up 2027 regulatory submission and expansion into solid tumors (Ref) Biotech’s updated Phase 3 ENLIGHTED trial data for padeliporfin VTP in low‑grade upper tract urothelial carcinoma

08/08/2025 Boehringer Ingelheim's Hernexeos received accelerated approval from the US FDA for HER2-mutant advanced NSCLC ( Ref ) The US...